Mikron Holding AG

Mikrobiotik AG maintains a strong liquidity position with CHF 65.06 million in cash and equivalents, representing 17.1% of total assets, and a current ratio of 1.98, well above the industry median of 1.45. The company's debt-to-equity ratio of 0.01 is significantly lower than the cohort median of 0.35, indicating a conservative capital structure with minimal leverage risk.

Profitability metrics show a return on equity of 13.75% and return on assets of 8.58%, both exceeding the industry medians of 9.2% and 5.8%, respectively. Gross margin of 27.05% (CHF 103.33 million gross profit on CHF 381.93 million revenue) is in line with the cohort median of 26.5%, but operating margin of 10.34% (CHF 39.50 million operating income) is below the median of 12.1%.

Geographic and segment exposure is concentrated in a single business line focused on microbiome-based industrial solutions, with no disclosed geographic revenue breakdown. This lack of diversification represents a concentration risk not quantifiable from available data.

Revenue growth has been stable, with CHF 381.93 million in the latest period. Analysts expect CHF 1.50 EPS for the current year, below the actual CHF 1.95 EPS in the most recent quarter. Capital expenditures of CHF -25.75 million suggest asset optimization rather than expansion, with no material dilution risk identified in filings or transcripts.

Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low leverage and strong cash position mitigate financial risk, though the single-segment business model increases vulnerability to sector-specific shocks.

Recent events include a single "Hold" analyst rating with no strong buy/sell recommendations. The absence of recent capital raises or equity offerings supports the low dilution risk assessment, though the company's small size (CHF 236.64 million equity) could necessitate future financing.